Cerveau, Alnylam partner on tau biomarker imaging agent for PET scans

Cerveau Technologies Inc. announced a partnership with Alnylam Pharmaceuticals, which will use Cerveau’s investigational imaging agent in positron emission tomography scans to evaluate neurofibrillary tangles in the brain.

According to a Cerveau release, the new collaboration highlights the use of the company’s [F-18]MK-6240 as a biomarker in Alnylam’s research and development of therapeutics for neurodegenerative diseases, with a focus on mild cognitive impairment and pre-symptomatic Alzheimer’s disease.

“Cerveau is focused on enabling acceleration of technologies that have the potential to advance the fight against debilitating neurodegenerative diseases,” Rick Hiatt, CEO of Cerveau Technologies, said in the release. “We are excited to add Alnylam to our growing network of pharmaceutical partners and global validated production sites. Our goal is to expand the availability of this novel investigational imaging agent to the broader scientific community.”